Parkinson's Disease Biospecimen Review Access Committee (PD-BRAC)
The PD-BRAC provides review for all requests for PD-related bio-specimens from the following biospecimen resources:
- The National Brain and Tissue Resource for Parkinson's Disease and Related Disorders, at the Banner Sun Health Research Institute, a cooperative agreement via the NINDS.
- BioFIND, a cross-sectional Parkinson's Disease Biomarkers Discovery project led by the Michael J. Fox Foundation (MJFF), in collaboration with the National Institute of Neurological Disorders and Stroke (NINDS).
- DATATOP, an intervention trial, conducted by the Parkinson Study Group in the late 1980s, from which samples are available.
- The LRRK2 Consortium Cohort, a study of people both with and without the LRRK2 gene, funded by the MJFF.
- The Parkinson's Disease Biomarkers Program, a longitudinal Parkinson's Disease Biomarkers discovery program, led by the NINDS.
The BRAC meets approximately every two months. Expedited review is possible. In order to request specimens, apply via X01-PAR-14-340. If that is not possible, please email your application with all aspects completed to the BRAC at NINDS-PD-BRAC@ninds.nih.gov
X01-PAR-14-340 applications for biospecimen access will be received on a rolling submission basis and reviewed during the following cycles:
- Submissions between October 13, 2014 - January 15, 2015
Review date: January 22, 2015 - Submissions between January 16 - March 15, 2015
Review date: April 2, 2015 - Submissions between March 16 - July 15, 2015
Review date: July 30, 2015 - Submissions between July 16 - September 15, 2015
Review date: October 1, 2015 - Submissions between September 16 - November 15, 2015
Review date: December 3, 2015
BRAC reviewers are required to avoid any real or perceived conflict of interest. The PD-BRAC subscribes to the ethical requirements for NIH reviewers, as described within the Conflict of Interest document.
BRAC Membership: Dr. Karen David is the PD BRAC Liaison. Dr. Mark Cookson is the BRAC Chair. Additional members (Display)
| Last Name | First Name | Study Association | Areas of Expertise |
|---|---|---|---|
| Babcock | Debra | NINDS | Cognition, imaging |
| Beach | Thomas | Banner Health Brain Banking | Neuropathologist |
| Bowman | DuBois | PDBP | Statistics, imaging |
| Chen-Plotkin | Alice | PDBP | Movement Disorders Clinician, SOMAlogics platform, proteomics |
| Cookson | Mark | NIA intramural | Cell Biology |
| Frasier | Mark | MJFF | Biochemistry and pharmacology, drug discovery, PD Biomarkers Programs, proteins |
| German | Dwight | PDBP | Inflammatory and immune mediated mechanisms of PD, blood biomarkers, environmental causes, metabolites |
| Gwinn | Katrina | NINDS | Movement Disorders Clinician, Genetics |
| Kalia | Lorraine | LRRK2 cohort | Clinical genetics of PD, molecular/cellular techniques, animal models |
| Kang | Un | BioFIND | Movement Disorders Clinician, Environmental Factors in PD, dopamine therapy |
| Kopil | Catherine (Katie) | MJFF | Cell biology, PD Biomarkers Programs, brain injury, bioengineering |
| Scherzer | Clemens | PDBP, Harvard Biomarkers Program | RNA, epigenomics |
| Schulman | Howard | Allosteros Therapeutics | Proteomics, (kinases, hormones, cytokines, etc) |
| Shaw | Chad | Baylor | Statistics, genomics, microarrays |
| Sieber | Beth-Anne | NINDS | Cellular and molecular aspects of neurodegeneration |
| Simon | David | DATATOP, FS-ZONE, Beth-Israel | Movement Disorders Clinician, Genetics, oxidative stress, mitochondria |
| Sutherland | Margaret | NINDS | PD Genetics, Animal Models,Biomarkers Programs |
Biospecimen Requests approved by the PD BRAC (Display)
| Approval Date | Last | First | Institution | Repository | Project Title |
|---|---|---|---|---|---|
| Feb-15 | Cai | Huaibin | NIH/NIA | Banner | Organization of Striosome and Matrix Compartments in Parkinson's disease |
| Feb-15 | Caviness | John | Mayo Clinic | Banner | Validation of Novel and Traditional Quantitative EEG Biomarkers for PD Cognition |
| Feb-15 | Christine | Chad | UCSF | DATATOP | Vitamin B12 in Parkinson's Disease |
| Apr-15 | German | Dwight | UT Southwestern | PDBP | Diagnostic and prognostic biomarkers for Parkinsons disease |
| Feb-15 | Hirst | Warren | Pfizer | Banner | Assessing glucocerebrosidase in sporadic Parkinson's disease - is GBA a valid target for sporadic Parkinson's disease |
| Nov-14 | Huang | Xuemei | Penn State (Hershey) | PDBP | Iron Management in Parkinson's Disease |
| Apr-15 | Ledeen | Robert | Rutgers | Banner | GM1 in intestinal tissues of Parkinson's disease |
| Apr-15 | Lograsso | Philip | Molecular Therapeutics | Banner | Assessment of JNK activation in Parkinson's disease patients with varying Lewy Body Pathology |
| Feb-15 | Meredith | Jere | Bristol-Myers Squibb | Banner | Determination of Optimal Epitopes for Parkinson's disease Immunotherapy |
| Feb-15 | Montine | Tom | Univ of Washington | Banner | Regional Molecular Pathologic Changes in PD and PDD with GBA Variants or APOE Epsilon 4 Allele |
| Apr-15 | Reed | Steven | Scripps | Banner | Fbw7 in idiopathic PD brains |
| Apr-15 | Roher | Alex | Banner | Banner | Quantitative and Morphological Assessment of REST in Parkinson's Disease and Normal Aging |
| Nov-14 | Singleton | Andrew | NIH-NIA Intramural | PDBP | NeuroX Chip Genetic Characterization of PDBP Collection |
| Apr-15 | Smith | Yoland | Emory | Banner | Degeneration of Glutamatergic Inputs to the Subthalamic Nucleus in Parkinson's Disease |
Participating Organizations:
